AKT1 and lung carcinoma: Combined TAE684 (ALK tyrosine kinase inhibitors) with PI3K inhibitor synergistically inhibited the proliferation of EML4-ALK-positive lung cancer cells and inhibition of PI3K/AKT signaling may conquer resistance to ALK-targeted treatment27.